Evidence map›Paper›PMID 31019638›Full record

ArticleCardiology research2019

Long-Term Survival After Stroke According to Reperfusion Therapy, Cardiovascular Therapy and Gender.

Jose Luis Clua-Espuny, Sonia Abilleira, Lluisa Queralt-Tomas, Antonia Gonzalez-Henares, Vicente Gil-Guillen, Eulalia Muria-Subirats, Juan Ballesta-Ors

Registry-linked trialAbstract read
In one paragraph

Article in Cardiology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03247036 (Long Survival After Ischemic Stroke and Thombolysis in Catalonia. Differences by Sex), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03247036 completednot on this map

Long Survival After Ischemic Stroke and Thombolysis in Catalonia. Differences by Sex

Typeobservational_patient_registrySponsorFundacio d'Investigacio en Atencio Primaria Jordi Gol i GurinaRan2017 to 2017Enrolled21,000ConditionsIschemic Stroke, Thrombolytic (t-PA) Treatment, Gender Bias, Long Term Adverse EffectsArmsIV thrombolytic (t-PA) treatment vs not
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jose Luis Clua-EspunyEAP-Tortosa 1-Est, Catalonian Health Institute, SAP Terres de l'Ebre, Health Department, Generalitat de Catalunya, CAP Temple, 43500 Tortosa, Spain.
Sonia AbilleiraStroke Programme, Agency for Health Quality and Assessment of Catalonia, CIBER Epidemiologia y Salud Publica (CIBERESP), Edifici Salvany, Roc Boronat 81-95, 2a planta 08005, Barcelona, Spain.
Lluisa Queralt-TomasEAP-Tortosa-2-Oest, Catalonian Health Institute, SAP Terres de l'Ebre, Health Department, Generalitat de Catalunya, CAP Xerta, Barcelona, 43592 Catalonia, Spain.
Antonia Gonzalez-HenaresDepartment of Research, ICS Terres de l'Ebre, Research Institute University Primary Care (IDIAP) Jordi Gol, Barcelona, Spain.
Vicente Gil-GuillenClinical Evidence Based Medicine and Emotional Department, Miguel Hernandez University, Family and Community Specialty, Crta. Nacional, N-332 s/n, 03550 Sant Joan (Alicante), Spain.
Eulalia Muria-SubiratsUUDD Tortosa-Terres de l'Ebre, Catalonian Health Institute, SAP Terres de l'Ebre, Health Department, Generalitat de Catalunya, CAP Temple, 43500 Tortosa, Spain.
Juan Ballesta-OrsUUDD Tortosa-Terres de l'Ebre, Catalonian Health Institute, SAP Terres de l'Ebre, Health Department, Generalitat de Catalunya, CAP Temple, 43500 Tortosa, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA wide variety of factors influence stroke prognosis, including age, stroke severity and comorbid conditions; but most current information about outcomes and safety is derived from patients at 3 - 12 months and mostly coming from the hospital activity. The aim of this study is to evaluate whether treatment strategies have a differential impact on long-survival after acute ischemic stroke among men versus women.

methodsAcute ischemic stroke patients identified from the population-based register between January 1, 2011 and December 31, 2012 were included, and they were classified into: 1) Acute ischemic stroke + intravenous thrombolysis (group I); 2) Acute ischemic stroke + mechanical thrombectomy with or without intravenous thrombolysis (group II); 3) Acute ischemic stroke + medical therapy alone (no reperfusion therapies) (group III). Follow-up went through up until December 2016. The probability of survival was estimated by the Kaplan-Meier method, and the hazard ratio was obtained by using the Cox proportional hazard regression models. Mortality was interpreted as overall mortality.

resultsA total of 14,368 cases (men 50.1%), 77.1 ± 11.0 years old were included. There was higher survival among those treated with intravenous thrombolysis (P < 0.001); women treated with thrombectomy (P < 0.001); and women < 80 years old without reperfusion therapy. The most common medications were antiplatelets (52.8%), associated with lower survival (P < 0.001); and statins (46.5%), associated with higher survival. The regression model produced the following independent outcome variables associated to mortality: anticoagulant hazard ratio (HR) 1.53 (95% confidence interval (95% CI): 1.44 - 1.63, P < 0.001), diuretics HR 1.71 (95% CI: 1.63 - 1.79, P < 0.001), antiplatelet HR 1.49 (95% CI: 1.42 - 1.56, P < 0.001), statins HR 0.73 (95% CI: 0.70 - 0.77; P < 0.001), angiotensin II receptor antagonists HR 0.93 (95% CI: 0.89 - 0.98, P = 0.008) and reperfusion therapy HR 0.88 (95% CI: 0.81 - 0.97, P = 0.009).

conclusionsMen and women have different prognoses after revascularization treatment for acute ischemic stroke. Under 80 years old the women appear to have a better outcome than men when treated with thrombolysis therapy and/or catheter-based thrombectomy. The chronic cardiovascular pharmacotherapy must be evaluated whether they should be included as factors in the decision to reperfusion.

Indexed as

Acute ischemic strokeChronic comorbiditiesLong-term survivalRevascularization therapySex

Identifiers

PMID31019638
PMCPMC6469916

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.